Can we incorporate MRD assessment into clinical practice in AML?

Best Pract Res Clin Haematol. 2019 Jun;32(2):186-191. doi: 10.1016/j.beha.2019.05.003. Epub 2019 May 10.


Measurable residual disease (MRD) can be assessed either by flow cytometry or molecular techniques. It has been proven to be highly prognostic in quite a number of prospective clinical studies. The recently published ELN MRD recommendations aim harmonize the approaches to MRD assessment in order to improve its overall quality. The predictive value leading to the usage as a surrogate endpoint for survival which would be instrumental for faster drug approvals has still to be proven. Nevertheless, many AML centers use MRD status to inform treatment.

Keywords: AML; Allogeneic stem cell transplantation; Leukemic stem cells; Measurable residual disease (MRD); Multicolor flowcytometry; qPCR.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Disease-Free Survival
  • Humans
  • Leukemia, Myeloid, Acute* / metabolism
  • Leukemia, Myeloid, Acute* / mortality
  • Leukemia, Myeloid, Acute* / pathology
  • Leukemia, Myeloid, Acute* / therapy
  • Neoplasm, Residual
  • Quality of Health Care*
  • Survival Rate